Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | CCR3 | P51677 | 4/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.48 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21358908 | 1.00 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2HSD11B1CCR3TACR3 | |
| SCHEMBL19994627 | 0.89 | MEN1 (0.55) | ALDH1A1CCR3MEN1POLBKMT2A | |
| SCHEMBL6083278 | 0.87 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HSD11B1CCR3PSEN1 | |
| SCHEMBL16600579 | 0.87 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HSD11B1CCR3PSEN1 | |
| SCHEMBL22470620 | 0.87 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2CCR3PSEN1PSEN2 | |
| SCHEMBL6975148 | 0.87 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2HSD11B1CCR3PSEN1 | |
| SCHEMBL31324479 | 0.87 | TACR3 (0.62) | ALDH1A1SMN1; SMN2HSD11B1TACR3MEN1 | |
| SCHEMBL31326493 | 0.86 | HSD11B1 (0.49) | ALDH1A1HSD11B1TACR3POLB | |
| SCHEMBL5582580 | 0.86 | HSD11B1 (0.49) | HSD11B1CCR3TACR3MEN1KMT2A | |
| SCHEMBL28131904 | 0.86 | EPHX2 (0.56) | HSD11B1TACR3POLBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879873-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK Holdings Co., Ltd. (KR) | 2008-01-23 | — | — | EP | disclosed |
| US-7230022-B2 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| WO-2006112685-A1 | NEUROTHERAPEUTIC AZOLE COMPOUNDS | SK HOLDINGS CO., LTD. (KR) | 2006-10-26 | — | — | WO | disclosed |
| US-6984651-B2 | Piperidine amides as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA, COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-08 | — | — | US | disclosed |
| WO-2005079497-A2 | SUBSTITUTED FUSED BICYCLIC AMINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | DUNCIA JOHN V (US) | 2004-04-29 | — | — | US | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6638950-B2 | Antiasthmatics and antiallergens, treating autoimmune pathologies such as rheumatoid arthritis and atherosclerosis | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-28 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| EP-1296978-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| EP-1296949-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Pharma Company (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-10-24 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001098268-A2 | PIPERIDINE AMIDES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156102-A1 | Piperidine amides as modulators of chemo kine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1698/4885SMN1; SMN2 2820/4885HSD11B1 4775/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885SMN1; SMN2 3813/4885HSD11B1 1213/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885SMN1; SMN2 3813/4885HSD11B1 1213/4885 |
| US-20040082790-A1 | Piperidine amides as modulators of chemokine receptor activity | CCR3, CCR1, CCL11 | ALDH1A1 722/4885SMN1; SMN2 3350/4885HSD11B1 2262/4885 |
| US-20050197373-A1 | Substituted fused bicyclic amines as modulators of chemokine receptor activity | CCR3, CCR1, CCR2 | ALDH1A1 2021/4885SMN1; SMN2 4503/4885HSD11B1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.